Technology
WHO recommends Oxford’s malaria vaccine for use
In October 2023 the University of Oxford announced that the WHO has recommended its malaria vaccine for the prevention of malaria in children.
WHO: southern hemisphere flu vaccine recommendations
In September 2023 the WHO announced recommendations for the viral composition of influenza vaccines for the 2024 influenza season in the southern hemisphere
BactiVac announces government funding: vaccines vs AMR
In September 2023 the University of Birmingham shared that the Bacterial Vaccines Network (BactiVac) was awarded £1.4 million by the UK government
Gritstone bio awarded BARDA contract for COVID-19 study
In September 2023 Gritstone bio announced that is has been awarded a contract by BARDA to conduct a Phase IIb comparative study that will evaluate
Revital gets Pre-Qualification: early activation AD syringe
In September 2023 Revital Healthcare announced a “historic milestone in African manufacturing excellence”. The company was awarded Pre-Qualification (PQ)
Vaccine start-ups return to the World Vaccine Congress!
In the last few weeks before the World Vaccine Congress in Barcelona, our start-up zone is reaching capacity! This week we are pleased to present another set of organisations that have already secured their spaces in the zone. To see previous introductions head over...
Cambridge shares further antigen technology success
The University of Cambridge announced in September 2023 that a vaccine antigen technology developed in collaboration with spin-out DIOSynVax in early 2020 demonstrated protection against all known variants of SARS-CoV-2 and other major coronaviruses. With a paper...
UKHSA and CSL Seqirus partnership: flu pandemic preparation
In September the UKHSA announced an agreed deal for “millions of life-saving vaccines” has been signed with CSL Seqirus. The advance purchase agreement (APA) ensures that CSL Seqirus is “on standby” to produce over 100 million influenza vaccines if an influenza...
Vir Biotechnology begins Phase I HIV vaccine trial
In September 2023 Vir Biotechnology announced that the first participant in a Phase I trial has been dosed. The trial of VIR-1388 will evaluate the safety, reactogenicity, and immunogenicity of the investigational novel T cell vaccine for the prevention of human...
Google’s DeepMind shares catalogue of disease insights
In September 2023 Google’s AI organisation, DeepMind, released a catalogue of genetic mutations intended to accelerate disease diagnosis and enable improvements to medical interventions. DeepMind, a team of “scientists, engineers, ethicists, and more” is “committed to...
Bio Farma and CEPI forge 10-year vaccine partnership
In September 2023 CEPI and Bio Farmer announced the agreement of a 10-year partnership to “boost rapid manufacturing of outbreak vaccines” at Indonesia’s “leading” vaccine manufacturer. This partnership is intended to bring mRNA and viral vector rapid response vaccine...
Vaccine start-ups return to the World Vaccine Congress!
With less than a month until the World Vaccine Congress in Barcelona, our start-up zone is continuing to grow! This week we are pleased to present another set of organisations that have already secured their spaces in the zone. To see previous introductions head over...
Oxford: PSI begins ChAdOx1 MERS vaccine trial
In September 2023 the University of Oxford’s Pandemic Sciences Institute (PSI) announced that a Phase I clinical trial for a vaccine against Middle East Respiratory Syndrome (MERS) had launched. This is the third Phase I clinical trial of the ChAdOx1 MERS vaccine but...
BioNTech and CEPI announce mRNA mpox partnership
In September 2023 BioNTech and CEPI announced a strategic partnership to advance mRNA-based vaccine candidates for the prevention of mpox. CEPI has stated that it will provide funding of up to $90 million to support the development of these vaccines. BioNTech’s...
CEPI and UC Davis partner on Rift Valley fever virus vaccine
In September 2023 CEPI and the University of California, Davis (UC Davis) announced a partnership to advance human trials of a novel vaccine against the “potentially deadly” Rift Valley fever virus (RVF). CEPI is expected to provide funding of up to $28.5 million,...
Oxford begins first-in-human trials for CCHF vaccine
In September 2023 the Oxford Vaccine Group (OVG) and Pandemic Sciences Institute (PSI) of the University of Oxford announced the commencement of a study investigating a vaccine against Crimean-Congo haemorrhagic fever (CCHF). The study is led by Professor Teresa...
Vaccine start-ups return to the World Vaccine Congress!
With just over a month until the World Vaccine Congress in Barcelona, our start-up zone is continuing to grow! This week we continue introducing organisations that have already secured their spaces in the zone. To see previous introductions head over to our...
An mRNA vaccine offers “promise” against Lassa virus
A paper published in Nature Communications in September 2023 presents the results of an investigation into the effects of mRNA vaccines against Lassa virus. The researchers suggest that vaccination induced “strong binding antibody responses”. However, Lassa...
Inverse vaccine could stop autoimmune reactions
A vaccine developed by researchers at the University of Chicago’s Pritzker School of Molecular Engineering (PME) has demonstrated in the lab that it can reverse autoimmune diseases without compromising the rest of the immune system. In a study in Nature Biomedical...
Research into intranasal RNA COVID-19 vaccines at MIT
A team at the Massachusetts Institute of Technology (MIT) is working on COVID-19 RNA vaccine optimisation to try and improve immune responses at lower doses. Results, published in Nature Biomedical Engineering suggest that their attempts to engineer both the...
